Acrannolife Genomics
Acrannolife Genomics is dedicated to developing innovative molecular diagnostics and precision healthcare solutions. Their mission is to positively impact over a billion lives by revolutionizing early diagnosis and monitoring of chronic and infectious diseases through advanced, non-invasive testing technologies. They focus on creating affordable, accessible, and accurate diagnostic platforms, including liquid biopsy and rapid testing kits, to improve patient outcomes globally.
Industries
Nr. of Employees
small (1-50)
Acrannolife Genomics
1st Floor, Block-III, Khivraj Complex, 480, Anna Salai, Nandanam, Chennai – 600035
Patents
Non-invasive method for monitoring transplanted organ status in organ-transplant recipients
US-11479819-B2
View Details
Non-invasive method for monitoring transplanted organ status in organ-transplant recipients
US-11479819-B2
View DetailsProducts
Non-invasive cfDNA liquid biopsy test for transplant monitoring
A blood-based diagnostic test that quantifies circulating and donor-derived cell-free DNA to assess solid-organ graft health and aid early detection of rejection; intended for periodic monitoring.
RT-LAMP-based rapid SARS-CoV-2 diagnostic kit
A swab-based RT-LAMP diagnostic kit for rapid detection of SARS-CoV-2 designed for use in low-infrastructure and mobile testing environments, providing results within 30–60 minutes.
Non-invasive cfDNA liquid biopsy test for transplant monitoring
A blood-based diagnostic test that quantifies circulating and donor-derived cell-free DNA to assess solid-organ graft health and aid early detection of rejection; intended for periodic monitoring.
RT-LAMP-based rapid SARS-CoV-2 diagnostic kit
A swab-based RT-LAMP diagnostic kit for rapid detection of SARS-CoV-2 designed for use in low-infrastructure and mobile testing environments, providing results within 30–60 minutes.
Services
Laboratory diagnostic service that analyzes blood-derived cell-free DNA to monitor solid-organ transplant health and detect rejection, offered to hospitals, transplant centres and patients with longitudinal sampling support.
Rapid nucleic-acid-based testing service using RT-LAMP chemistry designed for scalable mass testing at decentralized sites (institutions, public venues, mobile units) with short turnaround times and minimal infrastructure.
Laboratory diagnostic service that analyzes blood-derived cell-free DNA to monitor solid-organ transplant health and detect rejection, offered to hospitals, transplant centres and patients with longitudinal sampling support.
Rapid nucleic-acid-based testing service using RT-LAMP chemistry designed for scalable mass testing at decentralized sites (institutions, public venues, mobile units) with short turnaround times and minimal infrastructure.
Expertise Areas
- Transplant monitoring and post-transplant surveillance
- Liquid biopsy and cfDNA biomarker development
- Molecular assay development (nucleic acid amplification)
- Clinical validation and analytical performance reporting
Key Technologies
- Cell-free DNA (cfDNA) analysis
- Donor-derived cfDNA (ddcfDNA) assays
- Liquid biopsy
- RT-LAMP (reverse-transcription loop-mediated isothermal amplification)
News & Updates
A celebration marking 10 years of innovation, dedication, and impact, with awards and community bonding.
Feature highlighting the company's innovations in making healthcare solutions affordable and accessible across India.
An article discussing the challenges faced by transplant patients and how Acrannolife's tests aid in management.
Research on the potential of donor-derived cell-free DNA as a biomarker for liver transplant health, with high sensitivity and specificity.
Felicitation by the Honourable President of India
Recognition for their contributions to healthcare innovation.
Top Innovative Startup by India Innovation Growth Program (IIGP)
Awarded by Stanford University, University of Texas, DST, Govt of India, and FICCI.
A celebration marking 10 years of innovation, dedication, and impact, with awards and community bonding.
Feature highlighting the company's innovations in making healthcare solutions affordable and accessible across India.
An article discussing the challenges faced by transplant patients and how Acrannolife's tests aid in management.
Research on the potential of donor-derived cell-free DNA as a biomarker for liver transplant health, with high sensitivity and specificity.
Felicitation by the Honourable President of India
Recognition for their contributions to healthcare innovation.
Top Innovative Startup by India Innovation Growth Program (IIGP)
Awarded by Stanford University, University of Texas, DST, Govt of India, and FICCI.